ASSESSMENT OF IFOSFAMIDE-INDUCED CARDIOVASCULAR DYSFUNCTION

异环磷酰胺(IFF)是环磷酰胺的类似物，以前没有 据报道会导致严重的心脏功能障碍。一些患者接受了 大剂量干扰素诱导治疗自体骨髓 移植已经被观察到发展了临床证据 表现为呼吸困难、低氧血症和体重的充血性心力衰竭 收获。系列放射性核素左心室射血分数和/或 超声心动图以及已确定的完整血流动力学参数 通过肺动脉插管，已经并将在所有 住进MICU的患者被推定为IFF心脏毒性。全 患者将被监测是否有任何心律失常和/或证据 顽固性心源性休克。此外，心血管疾病的时间进程 复苏情况也将受到监测。抽象形式的初步数据有 已提交给临床研究发表。 然而，收集N.B.数据主要是出于临床原因，而且 这不应被解释为一个独立的研究项目。

Ifosfamide (IFF), an analog of cyclophosphamide, has not been previously reported to cause serious cardiac dysfunction. Some patients receiving high-dose IFF as induction therapy for autologous bone marrow transplantation have been observed to develop clinical evidence of congestive heart failure as manifested by dyspnea, hypoxemia, and weight gain. Serial radionuclide left ventricular ejection fractions and/or echocardiograms as well as complete hemodynamic parameters, as determined by pulmonary artery catheterizations, have been and will be followed in all patients admitted to the MICU with presumed IFF cardiac toxicity. All patients will be monitored for any arrhythmias and/or evidence of intractable cardiogenic shock. In addition, time course to cardiovascular recovery will also be monitored. Preliminary data in abstract form have been submitted to Clinical Research for publication. N. B. Data are being primarily collected for clinical reasons, however, and this should not be construed as an independent research project.